US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VanEck Environmental Services ETF

38.10

-0.1779-0.46%

Volume:4.70K

Turnover:180.09K

Market Cap:85.34M

PE:66.09

High:38.48

Open:38.23

Low:38.06

Close:38.28

Loading ...

Overview Company News Filings

Evaxion Biotech doses first patient in extension of phase 2 trial on EVX-01

Listen up, car dealers – you need to start selling EVs the way you sell tow rigs

Ecolab Navigates Soft Demand, Tariffs With Margin Gains, Confirms Full-Year Forecast

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

BMW is selling more EVs than Audi and Mercedes COMBINED – here’s why

BMW iX snatches the top spot in J.D. Power EV satisfaction survey

Donaldson Q2 Earnings Miss: Aftermarket And Life Sciences Segments Shine Amid Revenue Dip

Hyundai IONIQ 6 Named the Highest-Ranking Mass-Market BEV in J.D. Power 2025 U.S. Electric Vehicle Experience Ownership Study

Evaxion Biotech extends Phase 2 trial with EVX-01 to enhance clinical data

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Ecolab Q4: Solid EPS Growth, Industrial And Institutional Acceleration, 2025 Momentum And More

BRIEF-Vaneck Announces Change To ETF Product Line

Vaneck- Vaneck ETF Trust Approved a 5-for-1 Forward Stock Split for Vaneck Environmental Services ETF

THOMSON REUTERS

Evaxion Biotech completes dosing in phase 2 trial with EVX-01

Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/EVX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EVX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVX\",,,,,undefined,":{"symbol":"EVX","market":"US","secType":"STK","nameCN":"VanEck Environmental Services ETF","latestPrice":38.1,"timestamp":1750276800000,"preClose":38.2779,"halted":0,"volume":4701,"delay":0,"floatShares":2240000,"shares":2240000,"eps":0.576482,"marketStatus":"Pre-Mkt","change":-0.1779,"latestTime":"06-20 09:08:26 EDT","open":38.23,"high":38.476,"low":38.06,"amount":180093.7534,"amplitude":0.010868,"askPrice":45.76,"askSize":100,"bidPrice":31.81,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0.576482,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750426200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":38.06,"sharesOutstanding":2240000,"nav":38.07252,"aum":85282435.52,"dividendRate":0.004199,"bidAskSpread":0.002268,"postHourTrading":{"tag":"盘后","latestPrice":38.1,"preClose":38.1,"latestTime":"16:06 EDT","volume":6,"amount":226.3,"timestamp":1750277188763},"volumeRatio":1.1761909674763682,"impliedVol":0.0733,"impliedVolPercentile":0.241},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVX\",,,,,undefined,":{"symbol":"EVX","floatShares":2240000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1761909674763682,"shares":2240000,"dividePrice":0.16,"high":38.476,"amplitude":0.010868,"preClose":38.2779,"low":38.06,"week52Low":31.39,"pbRate":"--","week52High":38.476,"institutionHeld":0,"latestPrice":38.1,"eps":0.576482,"divideRate":0.004199,"volume":4701,"delay":0,"ttmEps":0.576482,"open":38.23,"prevYearClose":34.2841,"prevWeekClose":37.7799,"prevMonthClose":37.4885,"prevQuarterClose":35.4363,"fiveDayClose":37.5076,"twentyDayClose":37.4553,"sixtyDayClose":35.5147},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537295945","title":"Evaxion Biotech doses first patient in extension of phase 2 trial on EVX-01","url":"https://stock-news.laohu8.com/highlight/detail?id=2537295945","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537295945?lang=en_us&edition=fundamental","pubTime":"2025-05-22 20:05","pubTimestamp":1747915529,"startTime":"0","endTime":"0","summary":"Evaxion has dosed the first patient in its one-year extension of the ongoing phase 2 trial with its lead asset EVX-01. Designed with Evaxion’s AI-I...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-doses-first-patient-in-extension-of-phase-2-trial-on-evx-01?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-doses-first-patient-in-extension-of-phase-2-trial-on-evx-01?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVAX","EVX","BK4139"],"gpt_icon":0},{"id":"2533540909","title":"Listen up, car dealers – you need to start selling EVs the way you sell tow rigs","url":"https://stock-news.laohu8.com/highlight/detail?id=2533540909","media":"Electrek","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533540909?lang=en_us&edition=fundamental","pubTime":"2025-05-06 05:47","pubTimestamp":1746481678,"startTime":"0","endTime":"0","summary":"Professional salespeople love to talk about “the steps of the sale,” a tried-and-true process that guides every customer from curiosity to closed. But when it comes to electric cars, that old-school hustle can fall flat, leaving dealers struggling with how to fit them into their familiar playbook. But what if I told you, dear dealer, that there’s a whole category of vehicles on existing dealer lots that need to be approached in exactly the same way as an EV to score a successful sale that you’re already familiar with?","market":"us","thumbnail":"https://electrek.co/wp-content/uploads/sites/3/2025/05/my22-ram-3500-main.jpg?quality=82&strip=all&w=1600","type":0,"news_type":0,"thumbnails":["https://electrek.co/wp-content/uploads/sites/3/2025/05/my22-ram-3500-main.jpg?quality=82&strip=all&w=1600"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://electrek.co/2025/05/05/listen-up-car-dealers-you-need-to-start-selling-evs-the-way-you-sell-tow-rigs/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"electrek_highlight","symbols":["LU0661504455.SGD","GB00BDT5M118.USD","LU0154245756.USD","LU1917777945.USD","LU0648001328.SGD","BK4112","IE00BQXX3F31.USD","LU1153585028.USD","LU0256863811.USD","BK4588","LU0011850046.USD","LU2237957902.USD","LU0256863902.USD","LU0738911758.USD","LU0130102774.USD","LU2023250504.SGD","IE00BQXX3C00.GBP","LU2023250843.SGD","BK4585","LU0949170772.SGD","IE00BQXX3D17.EUR","LU0130517989.USD","LU0477156953.USD","LU0417517546.SGD","ICE","LU0154245673.USD","LU0390134368.USD","LU1201861249.SGD","LU1974910355.USD","LU0980610538.SGD","LU2237957811.SGD","SGXZ23171101.USD","LU2106854487.HKD","SG9999004303.SGD","LU0124676726.USD","LU0154236417.USD","LU0689626769.HKD","EVX"],"gpt_icon":0},{"id":"2531766380","title":"Ecolab Navigates Soft Demand, Tariffs With Margin Gains, Confirms Full-Year Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2531766380","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531766380?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:36","pubTimestamp":1745944588,"startTime":"0","endTime":"0","summary":"Ecolab Inc. (NYSE:ECL) reported Q1 sales of $3.69 billion, down 2% Y/Y and missing consensus estimate of $3.70 billion. Organic sales grew 3% Y/Y.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/45075654/ecolab-navigates-soft-demand-tariffs-with-margin-gains-confirms-full-year-forecast","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2272731600.USD","LU1712237335.SGD","LU2322448957.HKD","LU2298321311.HKD","LU1923622291.USD","LU2125910179.SGD","BK4109","LU2211814178.USD","LU2125909916.SGD","LU2272731865.HKD","LU1892829315.USD","LU2360108059.USD","LU2125910336.SGD","LU2125909759.SGD","LU2272731782.SGD","LU0323240290.USD","BK4585","LU2229751404.USD","LU0323239441.USD","EVX","LU1992135399.USD","IYM","LU1923622614.USD","LU2473716301.USD","LU2322448791.USD","LU2433249047.HKD","LU1923621640.USD","GB00BDT5M118.USD","LU2125909247.SGD","BK4588","BK4597","LU1992135472.HKD","LU2092937221.SGD","LU2125909593.SGD","ECL","LU2041044095.USD","LU1623119135.USD","LU2089279066.USD"],"gpt_icon":0},{"id":"2530024434","title":"80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530024434","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530024434?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidates. The data underscores the precision of Evaxion’s AI-Immunology platform in selecting therapeutically relevant vaccine targets. New findings show EVX-01 inducing a robust and durable immune response, further enhanced by booster immunizations. New immune data from the ongoing phase 2 trial with EVX-01 will be presented at a poster session tomorrow at the American Association for Cancer Research  Annual Meeting taking place in Chicago. The data demonstrates that 80% of EVX-01 vaccine targets triggered a tumor-specific immune response.“We are excited to report yet another positive set of data for our lead vaccine candidate EVX-01. Its ability to trigger an immune response is unprecedented compared to what has been reported by others. We are further encouraged by the data showing this response to be strong and long-lastin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/80-evx-01-vaccine-targets-120000202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","EVAX","LU1035773651.USD","BK4516","LU1061106388.HKD","LU0320765646.SGD","LU1066051225.USD","MRK","SGXZ57979304.SGD","LU1116320737.USD","IE00B4R5TH58.HKD","LU0289739699.SGD","LU0203345920.USD","LU1093756325.SGD","LU2324357040.USD","LU0203347892.USD","LU2112291526.USD","LU1989772840.SGD","SG9999015358.SGD","LU0965509010.AUD","LU1116320901.HKD","LU1023059063.AUD","SG9999015341.SGD","BK4559","BK4585","LU2023250504.SGD","LU0006306889.USD","LU0861579265.USD","SG9999002232.USD","LU0238689110.USD","SG9999001440.SGD","SG9999001176.SGD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","SG9999013999.USD","LU1941712264.USD","LU0211331839.USD","IE0009355771.USD","LU1929549753.HKD","LU0070302665.USD","EVX","LU0985320562.USD","LU1291159041.SGD","LU1934455277.USD","LU0106261372.USD","LU1066051498.USD","IE00BJJMRZ35.SGD","LU1066051811.HKD","LU1069347547.HKD","LU0208291251.USD"],"gpt_icon":0},{"id":"2521278785","title":"BMW is selling more EVs than Audi and Mercedes COMBINED – here’s why","url":"https://stock-news.laohu8.com/highlight/detail?id=2521278785","media":"Electrek","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521278785?lang=en_us&edition=fundamental","pubTime":"2025-03-24 03:52","pubTimestamp":1742759579,"startTime":"0","endTime":"0","summary":"We already know that BMW closed off 2024 with a banner year for its electrified “i” models – but it took a while for the larger picture to become clear. Not only is BMW succeeding with EVs, the Bavarians are outselling their two closest competitors combined. (!)","market":"us","thumbnail":"https://electrek.co/wp-content/uploads/sites/3/2025/03/BMW_i4_MAIN.jpg?quality=82&strip=all&w=1600","type":0,"news_type":0,"thumbnails":["https://electrek.co/wp-content/uploads/sites/3/2025/03/BMW_i4_MAIN.jpg?quality=82&strip=all&w=1600"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://electrek.co/2025/03/23/bmw-is-selling-more-evs-than-audi-and-mercedes-combined-heres-why/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"electrek_highlight","symbols":["EVX"],"gpt_icon":0},{"id":"2516152525","title":"BMW iX snatches the top spot in J.D. Power EV satisfaction survey","url":"https://stock-news.laohu8.com/highlight/detail?id=2516152525","media":"Electrek","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516152525?lang=en_us&edition=fundamental","pubTime":"2025-03-03 06:12","pubTimestamp":1740953526,"startTime":"0","endTime":"0","summary":"The 2025 US Electric Vehicle Experience (EVX) Ownership Study from J.D. Power tells us that more people are more satisfied with their EV experience than last year – and the EV owners who are the most satisfied with their rides can be found behind the wheel of the BMW iX.","market":"us","thumbnail":"https://electrek.co/wp-content/uploads/sites/3/2025/03/iX-Hero.jpg?quality=82&strip=all&w=1600","type":0,"news_type":0,"thumbnails":["https://electrek.co/wp-content/uploads/sites/3/2025/03/iX-Hero.jpg?quality=82&strip=all&w=1600"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://electrek.co/2025/03/02/bmw-ix-snatches-the-top-spot-in-j-d-power-ev-satisfaction-survey/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"electrek_highlight","symbols":["LU0417517546.SGD","LU0477156953.USD","PW","LU1917777945.USD","LU0154245756.USD","SGXZ23171101.USD","LU0124676726.USD","LU2237957811.SGD","BK4112","LU0390134368.USD","BK4234","LU0648001328.SGD","LU0256863811.USD","LU0661504455.SGD","LU2023250843.SGD","LU1974910355.USD","BK4588","SG9999004303.SGD","LU0256863902.USD","LU0689626769.HKD","LU1201861249.SGD","BK4585","LU2106854487.HKD","ICE","LU0738911758.USD","IE00BQXX3C00.GBP","LU0011850046.USD","LU0130517989.USD","LU0949170772.SGD","LU2237957902.USD","LU0154245673.USD","LU2023250504.SGD","IE00BQXX3F31.USD","EVX","LU0980610538.SGD","IE00BQXX3D17.EUR","LU0154236417.USD","LU1153585028.USD","BK4084","LU0130102774.USD","GB00BDT5M118.USD"],"gpt_icon":0},{"id":"2514956386","title":"Donaldson Q2 Earnings Miss: Aftermarket And Life Sciences Segments Shine Amid Revenue Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2514956386","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514956386?lang=en_us&edition=fundamental","pubTime":"2025-02-27 22:52","pubTimestamp":1740667962,"startTime":"0","endTime":"0","summary":"Donaldson Co., reported Q2 results with sales down 0.8%. Adjusted EPS of $0.83 missed consensus of $0.85. FY25 guidance revised.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/44008563/donaldson-q2-earnings-miss-aftermarket-and-life-sciences-segments-shine-amid-q2-revenue-dip","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVX","RNEW","DCI"],"gpt_icon":0},{"id":"2514877356","title":"Hyundai IONIQ 6 Named the Highest-Ranking Mass-Market BEV in J.D. Power 2025 U.S. Electric Vehicle Experience Ownership Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2514877356","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514877356?lang=en_us&edition=fundamental","pubTime":"2025-02-27 19:00","pubTimestamp":1740654000,"startTime":"0","endTime":"0","summary":"Hyundai IONIQ 6 sedan climbs to top spot in its segment, improving from third place and scoring more than 26 points above the mass-market battery electric vehicle  category average. Now in its fifth year, J.D. Power's EVX measures key satisfaction criteria including range, cost of ownership, quality and reliability. FOUNTAIN VALLEY, Calif., Feb. 27, 2025 /PRNewswire/ -- Hyundai continues to raise the bar in electric vehicle innovation and customer satisfaction, as today, the IONIQ 6sedan has been recognized as the highest-ranked mass-market battery electric vehicle in the J.D. Power 2025 U.S. Electric Vehicle Experience  Ownership Study. The IONIQ 6's standout performance highlights its superior design, range, quality, and cost of ownership. The comprehensive annual study evaluates consumer satisfaction with their new electric vehicles based on real-world ownership experiences, measuring key factors including range, driving enjoyment, charging convenience, and overall vehicle quality.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hyundai-ioniq-6-named-highest-110000433.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hyundai-ioniq-6-named-highest-110000433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PW","EVX","BK4084","BK4234","HYMLF","HYMTF","BK4099"],"gpt_icon":0},{"id":"2514409158","title":"Evaxion Biotech extends Phase 2 trial with EVX-01 to enhance clinical data","url":"https://stock-news.laohu8.com/highlight/detail?id=2514409158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514409158?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:26","pubTimestamp":1740489971,"startTime":"0","endTime":"0","summary":"Evaxion Biotech (EVAX) will further enhance the data package from its ongoing phase 2 trial with the company’s lead asset EVX-01 by extending the t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-extends-phase-2-trial-with-evx-01-to-enhance-clinical-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-extends-phase-2-trial-with-evx-01-to-enhance-clinical-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EVX","EVAX"],"gpt_icon":0},{"id":"2514096708","title":"Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096708","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514096708?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data. The additional third year of EVX-01 dosing may provide further insights into potential enhanced treatment effects and durability of induced immune response. COPENHAGEN, Denmark, February 25, 2025 - Evaxion Biotech A/S  , a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will further enhance the data package from its ongoing phase 2 trial with the company’s lead asset EVX-01 by extending the trial from two to three years. Designed with Evaxion’s AI-Immunology platform, EVX-01 is a personalized cancer vaccine being developed as a treatment for advanced melanoma .Convincing one-year phase 2 dataConvincing interim one-year data from the trial w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/evaxion-extends-phase-2-trial-130000084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999014542.SGD","LU2023250843.SGD","LU1291159041.SGD","SG9999013999.USD","LU2023250504.SGD","LU2461242641.AUD","LU0122379950.USD","LU0265550946.USD","SG9999015358.SGD","LU1934455194.USD","IE00BBT3K403.USD","LU1069347547.HKD","LU1585245621.USD","LU1934455863.HKD","LU1989772840.SGD","SG9999001176.SGD","SGXZ57979304.SGD","IE00B1BXHZ80.USD","SG9999002232.USD","IE00B4R5TH58.HKD","EVX","IE00BJJMRZ35.SGD","EVAX","LU1066053197.SGD","SG9999014559.SGD","LU1983299246.USD","BK4585","LU1430594728.SGD","LU1989771016.USD","LU1023059063.AUD","LU0203347892.USD","LU1941712348.USD","IE00BFTCPJ56.SGD","LU0238689110.USD","BK4139","LU1093756168.USD","LU1934455277.USD","IE00BLSP4239.USD","IE00BN8TJ469.HKD","SG9999001176.USD","LU0006306889.USD","LU0985320562.USD","LU2361044949.HKD","LU0211331839.USD","LU2361044865.SGD","BK4534","IE00BJT1NW94.SGD","LU0058720904.USD","BK4533"],"gpt_icon":1},{"id":"2510438002","title":"Ecolab Q4: Solid EPS Growth, Industrial And Institutional Acceleration, 2025 Momentum And More","url":"https://stock-news.laohu8.com/highlight/detail?id=2510438002","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510438002?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:56","pubTimestamp":1739285805,"startTime":"0","endTime":"0","summary":"Ecolab beat Q4 sales estimate, driven by 4% organic sales growth. Company expects strong performance in 2025.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43626120/ecolab-q4-solid-eps-growth-industrial-and-institutional-acceleration-2025-momentum-and-more","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVX","PHO","ECL"],"gpt_icon":0},{"id":"2506981601","title":"BRIEF-Vaneck Announces Change To ETF Product Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2506981601","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506981601?lang=en_us&edition=fundamental","pubTime":"2025-01-25 06:18","pubTimestamp":1737757119,"startTime":"0","endTime":"0","summary":"BRIEF-Vaneck Announces Change To ETF Product LineVanEck Environmental Services ETF EVX.P:VANECK ANNOUNCES CHANGE TO ETF PRODUCT LINEVANECK- VANECK ETF TRUST APPROVED A 5-FOR-1 FORWARD STOCK SPLIT FOR VANECK ENVIRONMENTAL SERVICES ETFSource text: ID:nBw6423d6aFurther company coverage: EVX.P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nFWN3OK0X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVX"],"gpt_icon":0},{"id":"2506981807","title":"Vaneck- Vaneck ETF Trust Approved a 5-for-1 Forward Stock Split for Vaneck Environmental Services ETF","url":"https://stock-news.laohu8.com/highlight/detail?id=2506981807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506981807?lang=en_us&edition=fundamental","pubTime":"2025-01-25 05:05","pubTimestamp":1737752737,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250124:nFWN3OK0X2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVX"],"gpt_icon":0},{"id":"2503453416","title":"Evaxion Biotech completes dosing in phase 2 trial with EVX-01","url":"https://stock-news.laohu8.com/highlight/detail?id=2503453416","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503453416?lang=en_us&edition=fundamental","pubTime":"2025-01-15 21:11","pubTimestamp":1736946683,"startTime":"0","endTime":"0","summary":"Evaxion Biotech (EVAX) has now completed the dosing of all 16 patients in its phase 2 trial with the company’s lead asset EVX-01. Designed with Eva...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-completes-dosing-in-phase-2-trial-with-evx-01?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-completes-dosing-in-phase-2-trial-with-evx-01?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVX","BK4139","EVAX"],"gpt_icon":0},{"id":"2503643186","title":"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01","url":"https://stock-news.laohu8.com/highlight/detail?id=2503643186","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503643186?lang=en_us&edition=fundamental","pubTime":"2025-01-15 21:00","pubTimestamp":1736946000,"startTime":"0","endTime":"0","summary":"Trial remains on track for completion and data readout in the second half of 2025. COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S  , a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, has now completed the dosing of all 16 patients in its phase 2 trial with the company’s lead asset EVX-01. Designed with Evaxion’s AI-Immunology platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advanced melanoma .EVX-01 is a personalized therapy designed with our AI-Immunology platform and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/evaxion-completes-dosing-phase-2-130000253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756168.USD","LU1066051811.HKD","IE000M9KFDE8.USD","LU1917777945.USD","IE00BSNM7G36.USD","IE00B1BXHZ80.USD","IE00BLSP4239.USD","LU0965508806.USD","SG9999001176.SGD","EVX","LU1035773651.USD","BK4534","LU1585245621.USD","BK4007","SGXZ57979304.SGD","LU0320765646.SGD","LU0965509283.SGD","LU0985320562.USD","MRK","LU0265550946.USD","LU1699723380.USD","LU1934455277.USD","LU2468319806.SGD","LU0058720904.USD","LU2023250504.SGD","BK4585","LU0122379950.USD","BK4516","LU1941712348.USD","LU0211331839.USD","LU0266013472.USD","BK4559","LU1066051225.USD","LU0070302665.USD","LU1037948541.HKD","EVAX","LU0203345920.USD","LU0265550359.USD","LU1934455863.HKD","LU1093756325.SGD","LU0289739699.SGD","LU0238689110.USD","LU2361044865.SGD","BK4533","LU1291159041.SGD","LU1430594728.SGD","LU0861579265.USD","LU2112291526.USD","LU1571399168.USD","IE00B4R5TH58.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-06","symbol":"EVX","defaultRemindTime":1738852200000,"type":"split","dateTimestamp":1738818000000,"forFactor":1,"toFactor":5,"ratio":0.2},{"date":"2024-12-23","symbol":"EVX","amount":0.7955,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Environmental Services ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"EVX","amount":1.45,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Environmental Services ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"EVX","amount":0.5588,"defaultRemindTime":1671460200000,"name":"VanEck Environmental Services ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"EVX","amount":0.3704,"defaultRemindTime":1640010600000,"name":"Market Vectors Environmental Ser","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVX\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-21","recordDate":"2015-12-23","paymentDate":"2015-12-28","value":0.68,"currency":"USD"},{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.531,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.32,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.3906,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVX\",market:\"US\",delay:false,,,undefined,":{}}}